Clinical Conversations: The Choice of Adrenaline Injectors – A Practical Approach for GPs | Part Two

Maria Said AM

writer

Maria Said AM

Registered Nurse; CEO of Allergy & Anaphylaxis Australia; Associate member of the Australasian Society of Clinical Immunology and Allergy

Claim CPD for this activity

Educational Activities (EA)

0 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0 minutes

These are activities that require reflection on feedback about your work.

MO
0 minutes

These are activities that use your work data to ensure quality results.

Maria Said AM

 

Two adrenalin injectors are now available and this allows the patients a choice, but GPs need to be familiar with both devices. RN Maria Said, the CEO of Allergy and Anaphylaxis Australia, discusses the devices and issues concerning the prescription and use of adrenaline injectors. This is a three-part article.

This is part two of a three part series.
Read part one
Read part three

Practice points

• The doctor and the patient to make a decision together on what device best suits that person’s needs.
• We must educate parents, carers, babysitters, grandparents, school teachers, childcare staff. People in workplaces who are at risk of anaphylaxis should have a couple of colleagues that know how to recognise symptoms and how to use the emergency medication.
• Any health professional could certainly speak with the distributors of both devices and they can call Allergy and Anaphylaxis Australia.
• People is to ask about shelf-life when they purchase these devices and try to get the longest shelf-life that they can.
• It’s not okay for someone to have one Epipen® and one Anapen. They have got to have the same device, so that they focus in an emergency situation and they don’t have to think about which device they have got.
• The devices themselves have actually got the steps for administration on the actual device.
• GPs should have an Epipen® trainer and an Anapen® trainer to show the patients and these can usually be accessed through those companies.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rod Baber

Prof Rod Baber

Menopausal Hormone Therapy - What Dose of Estrogen is Best?

Dr Adam Nelson

Dr Adam Nelson

Cardiovascular Benefits of GLP1s – New Evidence

Dr Kathleen McNamee, Prof Sonia Grover

Dr Kathleen McNamee, Prof Sonia Grover

Oral Contraceptive Pill in Teens

Prof Andrew Sindone

Prof Andrew Sindone

RSV and the Heart

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Maria Said AM

writer

Maria Said AM

Registered Nurse; CEO of Allergy & Anaphylaxis Australia; Associate member of the Australasian Society of Clinical Immunology and Allergy

Test your knowledge

Recent articles

Latest GP poll

Do you believe the current authority prescription system should be:

Modified but kept in place

0%

Eliminated entirely without replacement

0%

Maintained as is

0%

Completely replaced with an alternative system

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease